RNA logo

Avidity Biosciences, Inc. Common Stock

RNA

RNA: Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

more

Show RNA Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of RNA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by RNA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Aug. 01, 2023
  • Patent Title: Compositions and methods of treating muscle dystrophy Jul. 25, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 21, 2023
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 14, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 14, 2023
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jan. 17, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 17, 2023
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 13, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Nov. 15, 2022
  • Patent Title: Compositions and methods of treating muscle dystrophy Sep. 20, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 02, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jun. 21, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Apr. 26, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 22, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 15, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Nov. 23, 2021
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 07, 2021
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Jun. 08, 2021
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping May. 04, 2021
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Feb. 09, 2021
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 05, 2021
  • Patent Title: Egfr nucleic acids and uses thereof Dec. 29, 2020
  • Patent Title: Kras nucleic acids and uses thereof Dec. 08, 2020
  • Patent Title: Beta-catenin nucleic acids and uses thereof Nov. 24, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Oct. 13, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 29, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 04, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Nov. 26, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of RNA in WallStreetBets Daily Discussion

RNA News

Recent insights relating to RNA

CNBC Recommendations

Recent picks made for RNA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RNA

Corporate Flights

Flights by private jets registered to RNA